Radiation pneumonitis (RP) is a common toxicity following radiotherapy for thoracic malignancies, which can result in pulmonary fibrosis and a permanent decline in pulmonary function. Zachary Moore, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, describes a randomized Phase II study (NCT02496585) evaluating the safety and efficacy of nintedanib, a multiple tyrosine kinase inhibitor, in combination with a standard taper of prednisone in patients with RP. The results demonstrated a trend towards higher freedom from subsequent pulmonary exacerbations at one year following treatment compared to the placebo group. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.
